| [1] |
Stamellou E, Seikrit C, Tang SCW, et al. IgA nephropathy [J]. Nat Rev Dis Primers, 2023, 9(1): 67.
|
| [2] |
Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy [J]. Clin J Am Soc Nephrol, 2023, 18(6): 727-738.
|
| [3] |
Wang X, Zhou XJ, Qiao X, et al. The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk [J]. Theranostics, 2025, 15(2): 656-681.
|
| [4] |
Han S, Shang L, Lu Y, et al. Gut microbiome characteristics in IgA nephropathy: qualitative and quantitative analysis from observational studies [J]. Front Cell Infect Microbiol, 2022, 12: 904401.
|
| [5] |
Wang X, Liu J, Huoshen W, et al. Causal relationships between gut microbiota and IgA nephropathy: evidence from Mendelian randomization and microbiome validation [J]. Ren Fail, 2025, 47(1): 2522979.
|
| [6] |
Zhang R, Tang Y, Feng X, et al. Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression [J]. Gut Microbes, 2025, 17(1): 2458184.
|
| [7] |
He JW, Zhou XJ, Li YF, et al. Associations of genetic variants contributing to gut microbiota composition in immunoglobin a nephropathy [J]. mSystems, 2021, 6(1): e00819- e00820.
|
| [8] |
Tang Y, Zhu Y, He H, et al. Gut dysbiosis and intestinal barrier dysfunction promotes IgA nephropathy by increasing the production of Gd-IgA1 [J]. Front Med, 2022, 9: 944027.
|
| [9] |
Kinashi Y, Tanaka K, Kimura S, et al. Intestinal epithelium dysfunctions cause IgA deposition in the kidney glomeruli of intestine-specific Ap1m2-deficient mice [J]. EBioMedicine, 2024, 106: 105256.
|
| [10] |
Yao K, Zheng L, Chen W, et al. Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy [J]. Front Immunol, 2025, 16: 1438683.
|
| [11] |
Gleeson PJ, Benech N, Chemouny J, et al. The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis [J]. Sci Transl Med, 2024, 16(740): eadl6149.
|
| [12] |
He JW, Zhou XJ, Lv JC, et al. Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies [J]. Theranostics, 2020, 10(25): 11462-11478.
|
| [13] |
Zheng N, Xie K, Ye H, et al. TLR7 in B cells promotes renal inflammation and Gd-IgA1 synthesis in IgA nephropathy [J]. JCI Insight, 2020, 5(14): e136965.
|
| [14] |
Lee M, Suzuki H, Ogiwara K, et al. The nucleotide-sensing toll-like receptor 9/Toll-like receptor 7 system is a potential therapeutic target for IgA nephropathy [J]. Kidney International, 2023, 104(5): 943-955.
|
| [15] |
唐余燕，孙蔚倩，贺海东，等. 肠黏膜TLR4/NF-κB通路激活与伪无菌IgA肾病小鼠肾损害有关[J]. 细胞与分子免疫学杂志，2023, 39(10): 865-871.
|
| [16] |
Cheung CK, Alexander S, Reich HN, et al. The pathogenesis of IgA nephropathy and implications for treatment [J]. Nat Rev Nephrol, 2025, 21(1): 9-23.
|
| [17] |
Chai L, Luo Q, Cai K, et al. Reduced fecal short-chain fatty acids levels and the relationship with gut microbiota in IgA nephropathy [J]. BMC Nephrol, 2021, 22(1): 209.
|
| [18] |
Tan J, Dong L, Jiang Z, et al. Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling [J]. J Transl Med, 2022, 20(1): 382.
|
| [19] |
Tang YY, Zhang DL, Huang LS, et al. Gut microbial metabolite, sphingosine-1-phosphate (S1P), drives mesangial cell phenotypic transformation and accelerates progression of IgA nephropathy via CCL2-MET-FAK pathway [J]. Curr Res Microb Sci, 2025, 9: 100494.
|
| [20] |
Miao H, Zhang SJ, Wu X, et al. Tryptophan metabolism as a target in gut microbiota, ageing and kidney disease [J]. Int J Biol Sci, 2025, 21(10): 4374-4387.
|
| [21] |
Tang Y, Li Y, Yang X, et al. Intestinal metabolite TMAO promotes CKD progression by stimulating macrophage M2 polarization through histone H4 lysine 12 lactylation [J]. Cell Death Differ, 2026, 33(2): 314-326.
|
| [22] |
Dong Z, Zhang R, Shen L, et al. Gut microbiota and immunoglobulin A nephropathy: exploration of dietary intervention and treatment strategies [J]. Food Sci Nutr, 2025, 13(5): e70218.
|
| [23] |
Papista C, Lechner S, Ben Mkaddem S, et al. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction [J]. Kidney Int, 2015, 88(2): 276-285.
|
| [24] |
Li Y, Wan S, Liu J, et al. Causal relationship between dietary intake and IgA nephropathy: a mendelian randomization study [J]. Front Nutr, 2024, 11: 1400907.
|
| [25] |
Mertowska P, Mertowski S, Wojnicka J, et al. A link between chronic kidney disease and gut microbiota in immunological and nutritional aspects [J]. Nutrients, 2021, 13(10): 3637.
|
| [26] |
Meng Y, Zhao M, Ma Q, et al. Bifidobacterium bifidum alleviates adenine-induced acute kidney injury in mice by improving intestinal barrier function [J]. Food Funct, 2024, 15(15): 8030-8042.
|
| [27] |
Soylu A, Berktaş S, Sarıoglu S, et al. Saccharomyces boulardii prevents oral-poliovirus vaccine-induced IgA nephropathy in mice [J]. Pediatr Nephrol, 2008, 23(8): 1287-1291.
|
| [28] |
Lauriero G, Abbad L, Vacca M, et al. Fecal microbiota transplantation modulates renal phenotype in the humanized mouse model of IgA nephropathy [J]. Front Immunol, 2021, 12: 694787.
|
| [29] |
Zhao J, Bai M, Yang X, et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports [J]. Ren Fail, 2021, 43(1): 928-933.
|
| [30] |
Zhi W, Li A, Wang Q, et al. Safety and efficacy assessment of fecal microbiota transplantation as an adjunctive treatment for IgA nephropathy: an exploratory clinical trial [J]. Sci Rep, 2024, 14(1): 22935.
|
| [31] |
Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial [J]. Lancet, 2023, 402(10405): 859-870.
|
| [32] |
Tian C, Yan M, Guo J, et al. Yeast cell wall-mediated ileal targeted delivery system for IgA nephropathy therapy [J]. ACS Biomater Sci Eng, 2025, 11(3): 1498-1509.
|
| [33] |
Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction [J]. J Am Soc Nephrol, 2017, 28(4): 1306-1313.
|
| [34] |
Ding Q, Xue C, Gao X, et al. Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series [J]. J Nephrol, 2025, 38(9): 2997-3004.
|
| [35] |
Floege J, Lafayette R, Barratt J, et al. Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy [J]. Kidney Int, 2025, 108(4): 695-706.
|
| [36] |
Barratt J, Suzuki Y, Nguyen VA, et al. Safety, tolerability, and efficacy of mezagitamab (TAK-079) as add-on to standard of care therapy in individuals with primary IgA nephropathy: results from a phase 1b study [J]. J Am Soc Nephrol, 2024, 35(10S): FR-PO857.
|
| [37] |
Lin L, Ren H, Li X, et al. Prospective pilot study of plasma cell-targeted therapy with bortezomib in refractory IgA nephropathy [J]. Kidney Int Rep, 2025, 10(9): 3023-3031.
|
| [38] |
Kooienga L, Lo J, Lee EY, et al. Zigakibart demonstrates clinical safety and efficacy in a phase 1/2 trial of healthy volunteers and patients with IgA nephropathy [J]. Kidney Int, 2025, 108(3): 445-454.
|
| [39] |
Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial [J]. N Engl J Med, 2026, 394(7): 635-646.
|
| [40] |
Wu M, Cheng Y, Zhao X, et al. Efficacy and safety of belimumab in IgA nephropathy: real-world evidence [J]. Nephrol Dial Transplant, 2026, 41(6): 1037-1044.
|
| [41] |
Lafayette R, Barbour SJ, Brenner RM, et al. A phase 3 trial of atacicept in patients with IgA nephropathy [J]. N Engl J Med, 2026, 394(7): 647-657
|
| [42] |
Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria [J]. Kidney Int Rep, 2023, 8(3): 499-506.
|
| [43] |
Madan A, Park I, Yalavarthy R, et al. Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF/APRIL antagonist, in autoantibody-associated glomerulonephritis [J]. Nephrol Dial Transplant, 2024, 39(Suppl 1): gfae069-0431-1342.
|
| [44] |
Xu Y, Mo Y, Xu Y. Advances in novel biologics targeting BAFF/APRIL in the treatment of IgA nephropathy [J]. Cells, 2026, 15(3): 240.
|
| [45] |
Di Leo V, Gleeson PJ, Sallustio F, et al. Rifaximin as a potential treatment for IgA nephropathy in a humanized mice model [J]. J Pers Med, 2021, 11(4): 309.
|
| [46] |
Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases [J]. Aliment Pharmacol Ther, 2016, 43(S1): 27-36.
|
| [47] |
Bao L, Bian X, Ren L, et al. Different doses of hydroxychloroquine regulate the structure of intestinal flora and glycosyltransferase activity in rats with IgA nephropathy [J]. Immunobiology, 2025, 230(3): 152891.
|